Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin.
about
Phosphodiesterase 5 inhibitors for pulmonary hypertensionProstacyclin for pulmonary hypertension in adultsThe limits of oral therapy in pulmonary arterial hypertension managementDrug treatment of pulmonary hypertension in childrenPharmacotherapy for pulmonary hypertensionPulmonary arterial hypertension: a comparison between children and adultsLong term treatment of pulmonary arterial hypertension with beraprost, an oral prostacyclin analoguePulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertensionA pilot study of the effect of spironolactone therapy on exercise capacity and endothelial dysfunction in pulmonary arterial hypertension: study protocol for a randomized controlled trial.Diagnosis and management of primary pulmonary hypertension.Medical management of primary pulmonary hypertension.Sildenafil for pulmonary hypertension.Progressive splenomegaly after epoprostenol therapy in portopulmonary hypertension.Primary pulmonary hypertension in childhood.Epoprostenol in primary pulmonary hypertension.Pulmonary hypertension in collagen vascular disease.New approaches to the treatment of pulmonary hypertension: from bench to bedside.Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH).The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension.Current management of patients with pulmonary hypertension and right ventricular insufficiency.Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel reportSildenafil--a possible treatment for acute pulmonary hypertension during cardiac surgery.Novel therapeutics for the treatment of paediatric pulmonary arterial hypertension.Functional class and targeted therapy are related to the survival in patients with pulmonary arterial hypertension.Portopulmonary hypertension: challenges in diagnosis and management.Integrated care and optimal management of pulmonary arterial hypertensionMotivations of patients with pulmonary arterial hypertension to participate in randomized clinical trialsComparative Safety and Tolerability of Prostacyclins in Pulmonary Hypertension.Endothelin receptor antagonists in cardiology clinical trials.Current treatment options in systemic Sclerosis (Scleroderma).Endothelin in health and disease: endothelin receptor antagonists in the management of pulmonary artery hypertension.Bosentan: a dual endothelin receptor antagonist.Prostacyclin for pulmonary hypertension.Prostacyclin analogs stimulate receptor-mediated cAMP synthesis and ATP release from rabbit and human erythrocytes.Current and emerging therapy for primary pulmonary hypertension.Pulmonary hypertension in autoimmune rheumatic diseases: where are we now?Treatment of pulmonary hypertension: a promising new age.Treprostinil therapy for pulmonary artery hypertension.Disruption of the apelin-APJ system worsens hypoxia-induced pulmonary hypertensionProstacyclin in the intensive care setting.
P2860
Q24245844-45ACA75F-BC01-45AD-BEB9-D527B6DF0D38Q24246933-1E2A6E5E-7099-485D-BC03-F20AE597D771Q26773209-B98F787F-6D0B-41EA-8882-08F3DE399774Q26996078-8C9FB5E9-EBA1-475D-97C1-9647CECAEBCDQ27022763-4BE2BC4C-A92C-4A1B-8695-2F76383E3627Q27687320-C2FE8FE1-8B1C-4AAD-B20E-1159EFB0A497Q28364280-D805D755-7121-4C89-8981-A3468F33FB91Q28582609-97A9EEC5-1568-45A2-B2B7-791D6E0BFFE4Q30539790-15577235-9474-49E8-BFD1-237E12228CD7Q33145716-BDFBD1A4-C7C7-417E-90DC-DDFF97C2FD41Q33147339-4FF37B5B-E82E-4558-9E08-654975658559Q33213984-1F928BE4-1958-4B4F-A9A6-EBE5512F4B3CQ33329956-F5F94945-A9E5-44CF-B74D-3E4691396CE1Q33588070-3D008144-A91D-44AD-BBE3-DABAE56D45F3Q33592445-ADB1886F-226A-40C2-8C56-896C14CAFECEQ33592469-007349B8-7E41-4C82-A657-D841DE8D7E71Q33690368-9DACDC8B-B15A-4403-834B-03B1695CB94FQ33788506-98E6E962-CF5C-434D-89C0-FE4288192B23Q33844740-A06D3FCF-0E0E-484E-BA85-5EDB97E435DBQ34027507-306E0661-CC53-438B-AA95-51989C09C1E9Q34064492-9FAD405C-362A-4CF1-9068-E581092E5550Q34116359-15AE84E7-7490-4584-A439-A880D0B403BAQ34232006-F1F74DA4-0DF4-4187-9C7C-67E74ADFE723Q34384302-F6E8C3E0-CA91-43E0-A2D9-16683571AF50Q34409046-00635348-7DA0-4422-B3E5-C600F8D991FBQ34417785-19D024A9-6FC5-4E17-A7A4-0290BD4DB0C7Q34420636-10FAA70F-BBDE-47C0-B3C2-69E6127BCA54Q34508259-7C5629F5-7DEF-48B7-AB61-C6587ABFC26EQ34544685-D46B9E77-9345-4ABC-ABD4-CBB63BA2B389Q34567929-C902AE46-44D8-43D5-BB45-7C1420D154EEQ34631613-D0B09D6E-3496-4EC5-B041-7940320CD88AQ34707006-4DF8DEC8-98BA-46DD-B958-3949E2A348BEQ34758143-1D979E0A-4878-4D61-BA9F-784116C7922DQ34790785-0896DD97-1171-4A8F-BA8B-B0033FA7D586Q34796981-6ACE7125-F8F7-4FB6-A9EA-21FA41816A31Q34810661-A978AF6C-BDC5-4445-BDDB-B75F5923AC01Q34985847-22283D53-99AA-4C2D-9EC9-5F3D3195D0E6Q35001030-DFD73068-AF52-4A01-9490-55E538DE3CFAQ35040806-FCBF7C51-93F7-4BD7-9B5E-19BD54523997Q35050464-0A4E2C69-DB06-4384-96B4-F8E573C36D8B
P2860
Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh
1994年學術文章
@zh-hant
name
Survival in primary pulmonary ...... uous intravenous prostacyclin.
@en
Survival in primary pulmonary ...... uous intravenous prostacyclin.
@nl
type
label
Survival in primary pulmonary ...... uous intravenous prostacyclin.
@en
Survival in primary pulmonary ...... uous intravenous prostacyclin.
@nl
prefLabel
Survival in primary pulmonary ...... uous intravenous prostacyclin.
@en
Survival in primary pulmonary ...... uous intravenous prostacyclin.
@nl
P2093
P1476
Survival in primary pulmonary ...... uous intravenous prostacyclin.
@en
P2093
P304
P356
10.7326/0003-4819-121-6-199409150-00003
P407
P577
1994-09-01T00:00:00Z